Varicella-Zoster Virus (VZV) Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation – Risk Factors, Incidence, Course, and Outcomes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040170

Enrollment

300

Registered

2026-07-22

Start date

2026-04-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z94.8

Interventions

Group 1: Retrospektive Datenanalyse einer Vergleichskohorte, die ebenfalls zwischen 2010 und 2024 eine allogene Blutstammzelltransplantation in der Klinik für Hämatologie, Onkologie und Klinische Immu

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: VZV reactivation following allogeneic hematopoietic stem cell transplantation

Exclusion criteria

Exclusion criteria: Withdrawn consent form

Design outcomes

Primary

Measure	Time frame
First, the retrospective study aims to provide a detailed descriptive characterization of VZV infections following allogeneic hematopoietic stem cell transplantation in order to describe their course, clinical presentation, potential risk factors, treatments, complications, and long-term consequences. Second, interference statistics will be used to investigate a possible antileukemic effect of the infection. The primary endpoint of this part of the study is the occurrence of relapses.	—

Measure

Time frame

First, the retrospective study aims to provide a detailed descriptive characterization of VZV infections following allogeneic hematopoietic stem cell transplantation in order to describe their course, clinical presentation, potential risk factors, treatments, complications, and long-term consequences. Second, interference statistics will be used to investigate a possible antileukemic effect of the infection. The primary endpoint of this part of the study is the occurrence of relapses.

—

Secondary

Measure	Time frame
Secondary endpoints include overall survival, event-free survival, the incidence and severity of GvHD, as well as TRM and NRM	—

Countries

Germany

Contacts

Public ContactGuido Kobbe

Uniklinik Düsseldorf

kobbe@med.uni-duesseldorf.de+492118116826

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026